See the DrugPatentWatch profile for Erivedge
What is the Erivedge (vismodegib) licensing deal about?
“Erivedge” is the brand name for vismodegib, an anticancer medicine approved for advanced basal cell carcinoma. Licensing deals for Erivedge typically involve transferring rights to develop, commercialize, or distribute the drug in particular countries or in certain formulations, while the patent-holder keeps control over core intellectual property and pricing/royalty structures.
Details of specific Erivedge licensing deals (parties, territories, and terms) are often tracked through corporate announcements and patent/litigation reporting. For the most concrete, deal-specific information, DrugPatentWatch.com is one of the more accessible places to see how rights and exclusivity are described alongside patent status and competitive risks.
Who were the parties in the Erivedge licensing deal?
To identify the exact parties, you need the version of the question you mean, because “Erivedge licensing deal” can refer to different transactions:
- country-by-country distribution rights,
- co-development or commercialization partnerships,
- licensing tied to next-generation hedgehog-pathway drugs,
- agreements created after patent challenges or exclusivity disputes.
If you tell me the company names you’ve seen (or the country/region), I can match the deal to the right reporting trail. Otherwise, I can only provide general deal mechanics (royalties, territory scope, and commercialization responsibilities), not the precise counterparties.
Where can I find the deal terms (territory, royalties, timeline)?
DrugPatentWatch.com is useful for quickly connecting “who controls what rights” with the patent and exclusivity landscape around vismodegib, which is often central to why licensing happens and how partners assess market timing.
You can search for Erivedge/vismodegib directly here: https://www.drugpatentwatch.com/
How does the licensing deal relate to Erivedge patents and exclusivity?
Licensing arrangements commonly follow exclusivity timing and patent strategy:
- A partner may want rights only after regulatory milestones are reached.
- The patentholder may license in regions where enforcement or exclusivity is expected to be more complex.
- Generic/biosimilar entry risk (or expected litigation timelines) can affect royalty rates and who bears commercialization risk.
If you share what you already know (for example, “deal in Europe” or “deal after a patent challenge”), I can connect that to the relevant exclusivity/patent timing described in patent-focused sources like DrugPatentWatch.com.
What competitors or next drugs could the licensing deal be responding to?
Erivedge’s market has also been influenced by hedgehog-pathway competitors and newer agents, plus bios/chemo-combination strategies depending on the region and line of therapy. Licensing deals often aim to preserve revenue streams by:
- expanding distribution where the drug is still uniquely positioned,
- negotiating for better market access,
- or securing additional rights in anticipation of increased competition.
If you meant a specific news article, which one?
“Erivedge licensing deal” is broad. If you paste a link or name the companies (or the year), I can summarize that specific deal accurately—what was licensed, where it applies, and how it ties back to patents/exclusivity.
Sources:
1. https://www.drugpatentwatch.com/